{"hands_on_practices": [{"introduction": "Histopathological confirmation is the cornerstone of diagnosing necrobiosis lipoidica (NL). However, obtaining a diagnostic specimen is not always straightforward, as the pathology is often located deep within the skin. This exercise [@problem_id:4466155] challenges you to apply first principles of dermatopathology to select the optimal biopsy technique after an initial, nondiagnostic attempt, reinforcing the critical link between lesion morphology, underlying pathology, and procedural choice.", "problem": "A $45$-year-old woman with type $1$ diabetes mellitus of $20$ years’ duration presents with two slowly enlarging pretibial plaques. Each plaque has a yellow-brown, atrophic, shiny center with overlying telangiectasias and a violaceous erythematous rim. There is no ulceration. A prior superficial punch biopsy (limited to papillary and superficial reticular dermis) from the central portion of one plaque was nondiagnostic, showing only nonspecific dermal fibrosis without granulomatous inflammation. You are asked to decide the next diagnostic step to confirm necrobiosis lipoidica, justifying your choice using first principles of skin anatomy, lesion selection, and dermatopathology.\n\nWhich of the following is the most appropriate next step?\n\nA. Repeat a superficial punch biopsy from the atrophic center and send a specimen for direct immunofluorescence (DIF)\n\nB. Perform a deep incisional biopsy oriented perpendicular to the active erythematous border that includes full-thickness dermis and subcutis, and request step sections and Periodic acid–Schiff (PAS) stain\n\nC. Order Doppler ultrasound of the lower extremity arteries to assess for peripheral arterial disease as confirmatory testing\n\nD. Obtain bacterial, fungal, and mycobacterial cultures from a superficial swab to exclude infection as the confirmatory test\n\nE. Perform a broad shave biopsy of the telangiectatic center to minimize scarring while sampling the most apparent area", "solution": "The problem statement is evaluated for validity before proceeding to a solution.\n\n### Step 1: Extract Givens\n\n-   Patient: A $45$-year-old woman.\n-   Medical History: Type $1$ diabetes mellitus for $20$ years.\n-   Clinical Presentation: Two slowly enlarging pretibial plaques.\n-   Lesion Characteristics: Yellow-brown, atrophic, shiny center with overlying telangiectasias; violaceous erythematous rim; no ulceration.\n-   Previous Diagnostic Attempt: A superficial punch biopsy from the central portion of a plaque.\n-   Previous Biopsy Depth: Limited to papillary and superficial reticular dermis.\n-   Previous Biopsy Result: Nondiagnostic, showing only nonspecific dermal fibrosis without granulomatous inflammation.\n-   Objective: To determine the most appropriate next diagnostic step to confirm a suspected diagnosis of necrobiosis lipoidica.\n-   Constraint: The justification must be based on first principles of skin anatomy, lesion selection, and dermatopathology.\n\n### Step 2: Validate Using Extracted Givens\n\n-   **Scientific Grounding:** The problem is scientifically sound. The clinical description of the pretibial plaques in a patient with long-standing type $1$ diabetes is a classic presentation for necrobiosis lipoidica (NL). The failure of a superficial biopsy to be diagnostic is also a well-recognized and plausible clinical scenario, directly related to the known histopathology of the disease. The scenario is firmly rooted in established principles of dermatology and dermatopathology.\n-   **Well-Posedness:** The problem is well-posed. It asks for the \"most appropriate next step\" to confirm a specific, suspected diagnosis given a clear clinical history and a failed initial diagnostic test. The provided information is sufficient and relevant to allow for a logical deduction of the optimal procedure.\n-   **Objectivity:** The language is clinical, precise, and objective, describing observable findings and patient history without subjective or ambiguous terminology.\n\n### Step 3: Verdict and Action\n\nThe problem statement is valid. It presents a coherent, scientifically grounded clinical scenario that requires the application of fundamental medical principles to solve. Therefore, a full analysis will be performed.\n\n### Principle-Based Derivation\n\nThe suspected diagnosis is necrobiosis lipoidica (NL). To determine the optimal diagnostic procedure, we must first understand its pathophysiology and corresponding histopathology, and then analyze why the initial biopsy failed.\n\n1.  **Skin Anatomy and NL Pathophysiology:** The skin is composed of the epidermis, dermis (papillary and reticular layers), and the underlying subcutis (subcutaneous fat). NL is primarily a disease of the dermis. It is a granulomatous inflammatory condition characterized by altered (necrobiotic) collagen. Crucially, the inflammation in NL is typically most prominent in the **deep reticular dermis** and frequently extends into the septa of the **subcutis**, manifesting as a septal panniculitis. The upper dermis can be relatively spared or show only secondary changes like fibrosis and telangiectasias, while the overlying epidermis is often atrophic. This deep location of the primary pathology is a key principle.\n\n2.  **Lesion Selection:** A skin lesion often has different zones reflecting the stage of the disease process. In NL, the **active, advancing border** (described as a violaceous erythematous rim) is where the inflammatory process is most robust. This is the ideal site for biopsy to visualize the characteristic granulomatous inflammation. The **central portion** (described as yellow-brown, atrophic, and shiny) represents a later, \"burnt-out\" stage, where inflammation has subsided, leaving behind fibrosis, collagen degeneration, lipid deposition (which causes the yellow color), and epidermal atrophy. A biopsy from this central, sclerotic area is less likely to be diagnostic, especially for the inflammatory component.\n\n3.  **Analysis of the Failed Biopsy:** The initial biopsy was a **superficial punch biopsy** from the **central portion**, limited to the papillary and superficial reticular dermis. It failed for two reasons derived from the principles above:\n    -   **Incorrect Depth:** It was too superficial and did not reach the deep dermis and subcutis where the pathognomonic granulomatous inflammation is located.\n    -   **Incorrect Location:** It was taken from the inactive, fibrotic center rather than the active inflammatory border.\n    The result of \"nonspecific dermal fibrosis\" is precisely what one would expect from such a sampling technique in a late-stage NL lesion.\n\n4.  **Requirements for a Definitive Biopsy:** Based on this analysis, the ideal subsequent biopsy must:\n    -   **Be deep enough:** It must sample the entire thickness of the dermis and extend into the subcutaneous fat. An incisional or deep excisional biopsy is superior to a punch or shave biopsy for this purpose.\n    -   **Be taken from the correct location:** It should be harvested from the active, violaceous erythematous border.\n    -   **Be properly processed:** For granulomatous diseases, which can be focal, examining multiple levels of the tissue block (**step sections**) significantly increases the probability of finding the diagnostic features. Special stains, like Periodic acid–Schiff (PAS), are useful to rule out differential diagnoses such as deep fungal infections.\n\nSynthesizing these requirements leads to the conclusion that a deep incisional biopsy from the active border, with a request for step sections, is the most appropriate next step.\n\n### Option-by-Option Analysis\n\n**A. Repeat a superficial punch biopsy from the atrophic center and send a specimen for direct immunofluorescence (DIF)**\n\nThis option recommends repeating the two critical errors of the first biopsy: sampling from the inactive center and taking a superficial specimen. This technique will likely yield the same nondiagnostic result of fibrosis. Furthermore, while immune deposits can be found in blood vessels in NL, direct immunofluorescence (DIF) is not the standard or primary method for diagnosis. The definitive diagnosis relies on identifying the characteristic granulomatous pattern on routine hematoxylin and eosin (HE) staining.\n\n*Verdict:* **Incorrect**.\n\n**B. Perform a deep incisional biopsy oriented perpendicular to the active erythematous border that includes full-thickness dermis and subcutis, and request step sections and Periodic acid–Schiff (PAS) stain**\n\nThis procedure is designed to overcome the specific failures of the initial biopsy.\n-   **Deep incisional biopsy:** Ensures adequate depth to capture the pathology in the deep dermis and subcutis.\n-   **Active erythematous border:** Samples the location with the most active inflammation.\n-   **Full-thickness dermis and subcutis:** The precise tissue layers needing examination.\n-   **Step sections:** Maximizes the diagnostic yield for a potentially focal granulomatous process.\n-   **PAS stain:** A relevant stain to rule out deep fungal infection, a key differential diagnosis for granulomatous inflammation.\nThis option represents the textbook, principle-based approach to obtaining a definitive diagnosis of NL in this scenario.\n\n*Verdict:* **Correct**.\n\n**C. Order Doppler ultrasound of the lower extremity arteries to assess for peripheral arterial disease as confirmatory testing**\n\nDoppler ultrasound assesses blood flow in large arteries to diagnose peripheral arterial disease (PAD). While there is an association between diabetes and PAD, NL is a result of diabetic *micro*angiopathy (small vessel disease) and a granulomatous inflammatory reaction. Doppler ultrasound is a test for macrovascular disease and cannot provide a histopathological diagnosis of a skin condition. It is not a confirmatory test for necrobiosis lipoidica.\n\n*Verdict:* **Incorrect**.\n\n**D. Obtain bacterial, fungal, and mycobacterial cultures from a superficial swab to exclude infection as the confirmatory test**\n\nWhile infectious causes of granulomatous disease (especially deep fungal and mycobacterial infections) are in the differential diagnosis, a **superficial swab** is an entirely inadequate method for collecting a specimen. These organisms reside deep in the dermis or subcutis; a surface swab will only culture skin surface commensals and contaminants. A proper culture requires a deep tissue specimen, which would be obtained during the biopsy itself. Moreover, cultures can only exclude infection; they cannot *confirm* the diagnosis of NL.\n\n*Verdict:* **Incorrect**.\n\n**E. Perform a broad shave biopsy of the telangiectatic center to minimize scarring while sampling the most apparent area**\n\nA shave biopsy is, by definition, a superficial procedure that removes only the epidermis and the uppermost dermis. This is anatomically insufficient to reach the deep dermal and subcutaneous pathology of NL. Sampling the \"telangiectatic center\" repeats the error of biopsying the inactive, fibrotic portion of the lesion. While minimizing scarring is a consideration, a diagnostically inadequate procedure is of no value.\n\n*Verdict:* **Incorrect**.", "answer": "$$\\boxed{B}$$", "id": "4466155"}, {"introduction": "The clinical and even histopathological features of necrobiosis lipoidica can overlap with other necrobiotic granulomatous diseases. This problem [@problem_id:4466160] simulates a complex diagnostic scenario where you must differentiate NL from its critical mimic, necrobiotic xanthogranuloma (NXG), by synthesizing subtle histological clues with pivotal systemic laboratory findings. Mastering this level of clinicopathologic correlation is essential for identifying conditions with serious systemic associations, such as the paraproteinemia linked to NXG.", "problem": "A patient presents with indurated, atrophic, yellow–red plaques with telangiectasia on the lower extremities. A punch biopsy demonstrates a palisading granulomatous dermatitis with bands of degenerated collagen, admixed foam cells, and numerous elongated, needle-shaped cholesterol clefts within areas of necrobiosis. There is conspicuous perivascular lymphoplasmacytic inflammation but no caseation. Serum protein electrophoresis (Serum Protein Electrophoresis, SPEP) reveals a monoclonal immunoglobulin spike (monoclonal gammopathy), later typed as immunoglobulin G (IgG) with $\\kappa$ light chain restriction. Lipid panel shows only mild hypercholesterolemia.\n\nUsing the core definitions of palisading granulomatous dermatoses and the well-established clinicopathologic associations of necrobiosis lipoidica and necrobiotic xanthogranuloma, decide whether necrobiosis lipoidica remains a tenable leading diagnosis in light of the laboratory and histopathologic data, and identify the most appropriate next step.\n\nChoose the single best option:\n\nA. Necrobiosis lipoidica remains the leading diagnosis; the monoclonal gammopathy is incidental; initiate high-potency topical corticosteroids without additional systemic evaluation.\n\nB. Necrobiotic xanthogranuloma is more likely than necrobiosis lipoidica given the monoclonal gammopathy and cholesterol clefts; arrange hematology referral to evaluate for plasma cell dyscrasia and obtain systemic work-up.\n\nC. Granuloma annulare is most likely; no systemic evaluation is required because the monoclonal spike does not influence the dermatologic diagnosis.\n\nD. Plane xanthoma is the correct diagnosis; the histology is characteristic, and management should focus on lipid-lowering therapy alone.\n\nE. Necrobiosis lipoidica with secondary cholesterol cleft formation due to diabetes mellitus–related dyslipidemia best explains all findings; reassure the patient that malignancy work-up is unnecessary.", "solution": "The problem statement is subjected to validation prior to any attempt at a solution.\n\n### Step 1: Extract Givens\n- **Clinical Presentation:** A patient with \"indurated, atrophic, yellow–red plaques with telangiectasia on the lower extremities.\"\n- **Histopathology:** A punch biopsy shows \"a palisading granulomatous dermatitis with bands of degenerated collagen, admixed foam cells, and numerous elongated, needle-shaped cholesterol clefts within areas of necrobiosis.\" The infiltrate is described as a \"conspicuous perivascular lymphoplasmacytic inflammation but no caseation.\"\n- **Laboratory Data:** Serum Protein Electrophoresis (SPEP) reveals a \"monoclonal immunoglobulin spike (monoclonal gammopathy), later typed as immunoglobulin G (IgG) with $\\kappa$ light chain restriction.\" A \"lipid panel shows only mild hypercholesterolemia.\"\n- **Question:** Evaluate the tenability of necrobiosis lipoidica as the leading diagnosis in light of the new data and identify the most appropriate next step.\n\n### Step 2: Validate Using Extracted Givens\nThe problem provides a coherent and internally consistent clinical vignette. The terminology used is standard in the fields of dermatology, dermatopathology, and hematology. The combination of clinical, histological, and laboratory findings describes a recognized, albeit rare, disease entity. The problem is scientifically grounded, well-posed, objective, and contains sufficient information to allow for a logical deduction. There are no contradictions, factual errors, or ambiguities that would render it invalid.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. A solution will be derived by synthesizing the provided data.\n\n### Analysis of Findings\nThe presented case is a classic exercise in clinicopathologic correlation, requiring the integration of findings from physical examination, histopathology, and laboratory investigation to arrive at the correct diagnosis and management plan. The core of the problem lies in the differential diagnosis of palisading granulomatous dermatoses.\n\n1.  **Initial Differential Diagnosis:** The clinical presentation of yellow-red plaques on the lower extremities combined with a histopathologic pattern of palisading granulomatous dermatitis with collagen degeneration (necrobiosis) places the condition within the spectrum of necrobiotic granulomatous diseases. The primary differential includes necrobiosis lipoidica (NL), necrobiotic xanthogranuloma (NXG), and granuloma annulare (GA).\n\n2.  **Histopathologic Clues:** While all three entities can show necrobiosis, specific features in the biopsy point strongly away from NL and GA.\n    - **Foam cells and Cholesterol Clefts:** The presence of \"admixed foam cells\" and, critically, \"numerous elongated, needle-shaped cholesterol clefts\" is a hallmark feature of a xanthogranulomatous process. While older lesions of NL can sometimes exhibit secondary lipid deposition and occasional cholesterol clefts, their prominence as described is highly characteristic of NXG.\n    - **Lymphoplasmacytic Infiltrate:** The infiltrate is described as \"conspicuous perivascular lymphoplasmacytic.\" A dense infiltrate rich in plasma cells is another key feature pointing towards NXG, whereas the infiltrate in NL is typically more lymphohistiocytic.\n\n3.  **Systemic Laboratory Findings:** The discovery of a \"monoclonal immunoglobulin spike (IgG) with $\\kappa$ light chain restriction\" is the pivotal piece of evidence.\n    - **Association with NXG:** Necrobiotic xanthogranuloma is strongly associated with an underlying paraproteinemia in over $80\\%$ of cases. The most common type of paraprotein is IgG, and the most common light chain is $\\kappa$, matching the patient's findings precisely. This paraproteinemia may manifest as monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, or overt multiple myeloma.\n    - **Association with NL and GA:** Neither necrobiosis lipoidica nor granuloma annulare has a recognized, non-incidental association with monoclonal gammopathy. While a patient with NL could coincidentally have MGUS, the combination of a paraprotein with the specific histopathologic features (cholesterol clefts, plasma cells) makes a diagnosis of NXG overwhelmingly more probable than a coincidental finding.\n\n4.  **Synthesis and Final Diagnosis:** The constellation of findings—yellow-red ulcerative plaques, a necrobiotic granuloma with numerous cholesterol clefts and plasma cells, and an associated IgG $\\kappa$ monoclonal gammopathy—is the pathognomonic triad for necrobiotic xanthogranuloma. Necrobiosis lipoidica is no longer a tenable leading diagnosis.\n\n5.  **Next Step in Management:** A diagnosis of NXG mandates a comprehensive systemic evaluation to characterize the associated plasma cell dyscrasia. This requires referral to a hematologist for a work-up that may include bone marrow biopsy, skeletal survey, and quantitative immunoglobulin analysis to stage the condition and rule out multiple myeloma.\n\n### Evaluation of Options\n\n**A. Necrobiosis lipoidica remains the leading diagnosis; the monoclonal gammopathy is incidental; initiate high-potency topical corticosteroids without additional systemic evaluation.**\nThis option fails to synthesize the data correctly. It dismisses the monoclonal gammopathy, the most specific diagnostic clue, as incidental. This is clinically unsound, as the association between the specific histologic findings and the paraprotein is well-established for NXG. Proposing only topical therapy without a systemic work-up constitutes a significant departure from the standard of care and risks missing a serious underlying hematologic malignancy.\n**Verdict: Incorrect**\n\n**B. Necrobiotic xanthogranuloma is more likely than necrobiosis lipoidica given the monoclonal gammopathy and cholesterol clefts; arrange hematology referral to evaluate for plasma cell dyscrasia and obtain systemic work-up.**\nThis option correctly identifies necrobiotic xanthogranuloma as the most likely diagnosis by integrating the key differentiating features: the monoclonal gammopathy and the prominent cholesterol clefts on histology. It also recommends the appropriate and critical next step in management, which is a hematology referral for a systemic work-up of the associated plasma cell dyscrasia. This aligns perfectly with the established medical literature and clinical guidelines for NXG.\n**Verdict: Correct**\n\n**C. Granuloma annulare is most likely; no systemic evaluation is required because the monoclonal spike does not influence the dermatologic diagnosis.**\nThis option is incorrect on multiple grounds. The clinical and histopathologic picture (ulcerating plaques, prominent cholesterol clefts, plasma cells) is not typical for granuloma annulare. The assertion that the monoclonal spike does not influence the diagnosis is fundamentally flawed; systemic findings are crucial for clinicopathologic correlation, and in this case, the paraprotein is the definitive clue that distinguishes NXG from other granulomatous diseases.\n**Verdict: Incorrect**\n\n**D. Plane xanthoma is the correct diagnosis; the histology is characteristic, and management should focus on lipid-lowering therapy alone.**\nThis option is incorrect. The histology of plane xanthoma consists of sheets of dermal foam cells without the necrobiotic, palisading granulomatous features described in the biopsy. The described histology is not characteristic of plane xanthoma. Management would also be inappropriate, as the core issue is the paraproteinemia, not primarily dyslipidemia (which was only mild).\n**Verdict: Incorrect**\n\n**E. Necrobiosis lipoidica with secondary cholesterol cleft formation due to diabetes mellitus–related dyslipidemia best explains all findings; reassure the patient that malignancy work-up is unnecessary.**\nThis option is incorrect and dangerous. It speculatively introduces diabetes mellitus, which is not mentioned in the stem. More egregiously, it dismisses the monoclonal gammopathy and advises against a malignancy work-up. This is a critical error in judgment, as NXG carries a significant risk of being associated with multiple myeloma. Reassuring the patient against a malignancy work-up would be a serious medical error.\n**Verdict: Incorrect**", "answer": "$$\\boxed{B}$$", "id": "4466160"}, {"introduction": "Once a diagnosis of necrobiosis lipoidica is confirmed, management often focuses on mitigating inflammation at the active borders. Intralesional corticosteroid injection is a common and effective therapy, but its safe administration requires precise dose calculation. This practical exercise [@problem_id:4466141] provides hands-on practice in converting a treatment plan into a quantifiable total dose, a fundamental skill that bridges therapeutic knowledge with patient safety.", "problem": "In necrobiosis lipoidica, intralesional corticosteroid therapy is often applied along the active border to modulate localized granulomatous inflammation and prevent progression. Consider a single-session plan to administer triamcinolone acetonide along the entire lesion border, with injections evenly spaced at fixed intervals. Use the following foundational definitions: concentration is the mass of solute per unit volume, volume per injection is the administered liquid per injection site, dose per injection is the product of concentration and volume, and the number of injections equals the total border length divided by the spacing between injections. A patient has a lesion whose measured border length (circumference) is $10 \\ \\mathrm{cm}$. The treatment plan is to inject triamcinolone acetonide at a concentration of $5 \\ \\mathrm{mg} \\, \\mathrm{mL}^{-1}$, with a volume of $0.1 \\ \\mathrm{mL}$ per injection, placed every $1 \\ \\mathrm{cm}$ along the border. Assuming injections are placed at evenly spaced positions without overlap and the border length is traversed once, compute the total mass of triamcinolone acetonide administered in this session. Express your final result in milligrams (mg) as a single real number. No rounding is required.", "solution": "The problem is subjected to validation prior to any attempt at a solution.\n\n**Step 1: Extract Givens**\nThe problem statement provides the following data and definitions:\n-   Lesion border length: $L = 10 \\ \\mathrm{cm}$\n-   Concentration of triamcinolone acetonide: $C = 5 \\ \\mathrm{mg} \\, \\mathrm{mL}^{-1}$\n-   Volume per injection: $V_{inj} = 0.1 \\ \\mathrm{mL}$\n-   Spacing between injections: $d = 1 \\ \\mathrm{cm}$\n-   Definition of concentration: mass of solute per unit volume.\n-   Definition of dose per injection: the product of concentration and volume.\n-   Definition of the number of injections: total border length divided by the spacing between injections.\n-   Condition: Injections are evenly spaced without overlap, and the border is traversed once.\n-   Objective: Compute the total mass of triamcinolone acetonide administered in milligrams (mg).\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is assessed for validity:\n-   **Scientifically Grounded:** The context and parameters describe a standard dermatological procedure (intralesional corticosteroid therapy for necrobiosis lipoidica). The specified concentration and volumes are clinically realistic. The underlying principles are basic dimensional analysis and arithmetic. The problem is scientifically sound.\n-   **Well-Posed:** The problem provides all necessary quantities and definitions to compute a unique numerical answer for the total administered mass. It is self-contained and unambiguous.\n-   **Objective:** The language is technical and free of subjective or opinion-based statements.\n-   **Consistency and Feasibility:** The given values are dimensionally consistent and physically feasible. The definition for the number of injections ($L/d$) is an explicit instruction that resolves any potential ambiguity regarding the treatment of endpoints on a closed loop. Since $L=10 \\ \\mathrm{cm}$ and $d=1 \\ \\mathrm{cm}$, the ratio is an integer, simplifying the interpretation further.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid as it is scientifically grounded, well-posed, objective, and internally consistent. A solution will be derived.\n\nThe total mass of triamcinolone acetonide, denoted as $M_{total}$, can be calculated as the product of the total number of injections, $N$, and the mass of the drug administered per injection, $m_{inj}$.\n$$M_{total} = N \\times m_{inj}$$\n\nFirst, we determine the total number of injections, $N$. The problem explicitly defines this as the total border length, $L$, divided by the spacing between injections, $d$.\n$$N = \\frac{L}{d}$$\nSubstituting the given values:\n$$N = \\frac{10 \\ \\mathrm{cm}}{1 \\ \\mathrm{cm}} = 10$$\nThus, a total of $10$ injections are administered.\n\nNext, we determine the mass of triamcinolone acetonide per injection, $m_{inj}$. The problem defines this dose as the product of the concentration, $C$, and the volume per injection, $V_{inj}$.\n$$m_{inj} = C \\times V_{inj}$$\nSubstituting the given values:\n$$m_{inj} = \\left(5 \\ \\frac{\\mathrm{mg}}{\\mathrm{mL}}\\right) \\times (0.1 \\ \\mathrm{mL})$$\nThe units of volume ($\\mathrm{mL}$) cancel, yielding a result in mass ($\\mathrm{mg}$).\n$$m_{inj} = 5 \\times 0.1 \\ \\mathrm{mg} = 0.5 \\ \\mathrm{mg}$$\nEach injection delivers a dose of $0.5 \\ \\mathrm{mg}$.\n\nFinally, we compute the total administered mass, $M_{total}$, by multiplying the number of injections by the mass per injection.\n$$M_{total} = N \\times m_{inj}$$\nSubstituting the calculated values for $N$ and $m_{inj}$:\n$$M_{total} = 10 \\times 0.5 \\ \\mathrm{mg} = 5 \\ \\mathrm{mg}$$\n\nThe total mass of triamcinolone acetonide administered in this session is $5 \\ \\mathrm{mg}$.", "answer": "$$\n\\boxed{5}\n$$", "id": "4466141"}]}